IFITM1: A Potential Drug Target and Biomarker for diseases (G8519)

Target Name: IFITM1

NCBI ID: G8519

IFITM1

IFITM1: A Potential Drug Target and Biomarker for diseases

IFITM1 (dispanin subfamily A member 2a) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its function is not well understood, but it is known to be involved in the regulation of cell survival and proliferation. Based on this, IFITM1 has been identified as a potential drug target and biomarker for various diseases.

IFITM1 and Cell Survival

IFITM1 is known to be involved in the regulation of cell survival and proliferation. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that IFITM1 is involved in the regulation of cell proliferation and has been shown to promote the growth and survival of cancer cells.

IFITM1 and Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. These diseases are often treated with drugs that aim to slow down or stop the progression of neurodegeneration. However, the underlying mechanisms of these diseases are not well understood.

IFITM1 has been shown to be involved in the development and progression of neurodegenerative diseases. Studies have shown that IFITM1 is expressed in the brains of individuals with Alzheimer's disease and that its levels are correlated with the severity of the disease. Additionally, research has shown that IFITM1 is involved in the regulation of neurodegenerate diseases, including the development of neurofibrillary tangles and the progression of neurodegeneration.

IFITM1 and Autoimmune Disorders

Autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, are characterized by the immune system attacking the body's own tissues. These disorders are often treated with drugs that aim to reduce the immune response and prevent the progression of tissue damage. However, the underlying mechanisms of these disorders are not well understood.

IFITM1 has been shown to be involved in the regulation of autoimmune disorders. Studies have shown that IFITM1 is expressed in the tissues of individuals with rheumatoid arthritis and that its levels are correlated with the severity of the disease. Additionally, research has shown that IFITM1 is involved in the regulation of autoimmune disorders, including the development of neurofibrillary tangles and the progression of autoimmune diseases.

IFITM1 as a Potential Drug Target

The potential drug targets for IFITM1 are based on its involvement in the regulation of cell survival and proliferation.IFITM1 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

IFITM1 has also been shown to be a good candidate for a drug target in its own right.IFITM1 has been shown to interact with various drug targets, including the PI3K/Akt signaling pathway, the TGF-β pathway, and the NF-kappa-B pathway.IFITM1 has also been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and invasion.

IFITM1 as a Biomarker

IFITM1 has also been shown to be a potential biomarker for various diseases.IFITM1 has been shown to be expressed in the brains of individuals with Alzheimer's disease and that its levels are correlated with the severity of the disease. Additionally, research has shown that IFITM1 is involved in the regulation of neurodegenerate diseases, including the development of neurofibrillary tangles and the progression of neurode

Protein Name: Interferon Induced Transmembrane Protein 1

Functions: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) (PubMed:26354436, PubMed:33270927). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration (PubMed:33270927). Inhibits SARS-CoV-2 S protein-mediated syncytia formation (PubMed:33051876). Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436)

The "IFITM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFITM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets